Looking at other TCGA tumor types in which the predominant genomic alteration in RB1 was the HD over other deleterious mutations, like prostate and ovarian cancers, the same phenomenon was observed and no significant differences were found in the amount of immunity effectors between the RB1 HD and the RB1 WT (data not shown). The gene discussed is RB1; the disease is ovarian cancer.